C R Bard Inc  

(Public, NYSE:BCR)   Watch this stock  
Find more results for BCR
-2.02 (-1.19%)
Mar 31 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 166.87 - 170.34
52 week 132.81 - 180.35
Open 168.49
Vol / Avg. 0.00/584,059.00
Mkt cap 12.59B
P/E 44.50
Div/yield 0.22/0.53
EPS 3.76
Shares 74.89M
Beta 0.72
Inst. own 91%
Apr 20, 2015
Q1 2015 C R Bard Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Apr 15, 2015
C R Bard Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
Mar 11, 2015
C R Bard Inc at Barclays Healthcare Conference
Mar 4, 2015
C R Bard Inc at Raymond James Institutional Investors Conference
Jan 29, 2015
Q4 2014 C R Bard Inc Earnings Call - Webcast
Jan 29, 2015
Q4 2014 C R Bard Inc Earnings Release
Jan 13, 2015
C R Bard Inc at JPMorgan Healthcare Conference (Q&A)
Jan 13, 2015
C R Bard Inc at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 15.48% 8.86%
Operating margin 21.61% 14.54%
EBITD margin - 28.88%
Return on average assets 10.55% 5.81%
Return on average equity 29.11% 14.88%
Employees 13,900 -
CDP Score - -


730 Central Ave
United States - Map
+1-908-2778000 (Phone)
+1-908-2778412 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


C. R. Bard, Inc. (Bard) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. The Company participates in the markets for vascular, urology, oncology and surgical specialty products. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD) and heart arrhythmias. Bard�s urology products include basic drainage products, continence products and urological specialty products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Bard has a line of products for inguinal (groin) hernias, including the Perfix Plug and three dimensional Max product lines.

Officers and directors

Timothy M. Ring Chairman of the Board, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John H. Weiland President, Chief Operating Officer, Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jim C. Beasley Group President
Age: 51
Bio & Compensation  - Reuters
Timothy P. Collins Group President
Age: 54
Bio & Compensation  - Reuters
Christopher S. Holland Chief Financial Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Samrat S. Khichi Senior Vice President, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
John A. DeFord Ph.D. Senior Vice President - Science, Technology and Clinical Affairs
Age: 53
Bio & Compensation  - Reuters
Frank Lupisella Jr. Vice President, Controller
Age: 54
Bio & Compensation  - Reuters
Patricia G. Christian Vice President - Quality, Regulatory and Medical Affairs
Age: 54
Bio & Compensation  - Reuters
John P. Groetelaars Group Vice President
Age: 48
Bio & Compensation  - Reuters